Amneal Pharmaceuticals, Inc. (AMRX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NYSE: AMRX). Investors who purchased Amneal securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Amneal has violated federal securities laws.

Investigation Details:

On July 3, 2023, Amneal issued a press release “announc[ing] it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for IPX203 for the treatment of Parkinson’s disease.”  The Company stated that “[t]he letter indicated that although an adequate scientific bridge was established for the safety of one ingredient, levodopa (LD), based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa (CD), and FDA has requested additional information.”  On this news, Amneal’s stock price fell $0.29 per share, or 9.51%, to close at $2.76 per share on July 5, 2023, the following trading day.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Amneal shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.  Our firm has recovered hundreds of millions of dollars for investors nationwide. 

Attorney advertising. Prior results do not guarantee similar outcomes.